Should their doctors agree, breast cancer patients with scleroderma may undergo radiation therapy — despite research suggesting it increases the risk of scarring in the skin, lungs and other organs, a team of American scientists has concluded. The previous studies’ small sample size — fewer than four patients — makes…
The first clinical symptom at onset, also called the mode of onset, should be considered a prognostic factor in patients with systemic sclerosis (SSc), new research shows. The study. “First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study,”…
Systemic sclerosis affects quality of life and places a financial burden on the healthcare system, a study indicates. The research, “Humanistic and cost burden of systemic sclerosis: A review of the literature,” was published in the journal Autoimmunity Reviews. Although systemic sclerosis is thought of as…
Male gender and certain lung function parameters are potential risk factors for the progression of pulmonary arterial hypertension in patients with systemic sclerosis-PAH (SSc-PAH), an analysis of the DETECT study shows. The research, “Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from…
Nintedanib alleviated the core manifestations of systemic sclerosis, resulting in a marked improvement in the disease, a study in mice has shown. The research, published in the Annals of the Rheumatic Diseases, was titled “Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the…
Inventiva Pharma, which develops therapies for fibrotic diseases, said the World Health Organization (WHO) has granted the International Non-Proprietary Name lanifibranor for IVA337. Lanifibranor is Inventiva’s lead drug candidate now being investigated to treat systemic sclerosis (SSc) and non-alcoholic steatohepatitis (NASH). The anti-fibrotic drug functions by activating three isoforms of…
The prevalence of autoantibodies, particularly Anti-Topo I, anti-CENP, and anti-RNA pol III, in patients with systemic sclerosis (SSc) can aid in predicting disease outcome, Greek researchers have found. Their study, “Disease-related autoantibody profile in patients with systemic sclerosis,” appeared in the journal Autoimmunity. SSc is characterized…
Get regular updates to your inbox.